BCR-ABL Truncation Mutations in Kinase Inhibitor Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current kinase inhibitor therapies, such as imatinib, face challenges with resistance due to mutations in the BCR-ABL protein, particularly truncation mutations that affect the kinase domain and C-terminal region, leading to reduced efficacy in treating myeloproliferative diseases like CML and ALL.
Innovation Solution
Identification and characterization of novel BCR-ABL nucleic acid variants, including deletions, insertions, and substitutions (Del 2595-2779, Del 2596-2597, 2417insCAGG, and C2506T), which result in truncated proteins conferring resistance to kinase inhibitors, along with methods for detecting these mutations and predicting treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If kinase inhibitor therapy (e.g., imatinib) is used to treat myeloproliferative diseases, then treatment efficacy is improved, but resistance develops due to BCR-ABL truncation mutations
Solution Approach 1:
The patent applies preliminary action by detecting BCR-ABL truncation mutations before initiating kinase inhibitor therapy. This allows clinicians to identify patients who are likely to develop resistance and select alternative treatments in advance, preventing treatment failure before it occurs. The detection methods described enable pre-treatment assessment of mutation status, allowing for personalized treatment selection that anticipates and prevents resistance development.
2Reliability
If standard kinase inhibitors are used, then initial treatment response is achieved, but secondary resistance occurs leading to hematologic recurrence
Solution Approach 1:
The patent implements feedback mechanisms by establishing detection methods that can identify BCR-ABL truncation mutations at various stages of treatment. This feedback loop allows clinicians to monitor treatment response and detect emerging resistance mutations, enabling timely adjustment of therapy. The feedback system continues throughout the treatment duration, providing ongoing information about mutation status that guides long-term treatment decisions and helps maintain durable responses.
3Reliability
If kinase inhibitor therapy is administered, then patient survival is improved, but treatment options are limited due to lack of alternatives for resistant patients
Solution Approach 1:
The patent applies segmentation by categorizing BCR-ABL mutations into distinct types, particularly identifying truncation mutations as a separate category from other resistance mechanisms. This segmentation allows for targeted detection methods specific to truncation mutations and enables clinicians to differentiate between patients with truncation mutations versus other mutation types. The segmented approach facilitates more precise treatment selection and expands therapeutic options by matching specific mutation subtypes with appropriate alternative therapies.
Data Source
AI summary
Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.